{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:26Z","timestamp":1794587246572,"version":"4.9.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Dongguan Social Development Science and Technology Project","award":["20231800926372"],"award-info":[{"award-number":["20231800926372"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis and low overall survival. Tuoli Xiaozheng Formula (TLXZF), a traditional Chinese compound prescription, has shown clinical efficacy in treating HCC, but its multi-component and multi-target mechanisms remain unclear. This study aimed to elucidate the molecular mechanisms of TLXZF against HCC by integrating network pharmacology, molecular docking, and Mendelian randomization (MR) analyses. Active compounds and targets were identified from the Traditional Chinese Medicine Systems Pharmacology, high-throughput experiment- and reference-guided database of traditional Chinese medicine, and SwissTargetPrediction databases, while HCC-related targets were obtained from Online Mendelian Inheritance in Man, GeneCards, DrugBank, and therapeutic target database. The intersection yielded 227 overlapping targets. Network analysis revealed quercetin, kaempferol, stigmasterol, luteolin, and isorhamnetin as core bioactive components, and protein\u2013protein interaction network analysis identified TP53, AKT1, CTNNB1, EGFR, IL-6, STAT3, TNF, BCL-2, and CASP3 as key targets. Kyoto Encyclopedia of Genes and Genomes enrichment indicated that TLXZF mainly acts through PI3K-AKT, MAPK, and HIF-1 signaling pathways. Molecular docking confirmed stable binding between core compounds and targets. MR analysis indicated that genetically predicted AKT1 levels were modestly associated with a reduced risk of HCC (odds ratio\u2005=\u20050.9986,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.000758), although the effect size was close to the null, suggesting a weak but statistically detectable lifelong genetic association. Overall, this integrative analysis suggests that TLXZF may exert its effects on HCC through a synergistic \u201cmulti-component-multi-target-multi-pathway\u201d regulatory pattern, primarily involving oncogenic, inflammatory, and survival-related signaling networks. These findings are hypothesis-generating and provide an initial basis for the identification and screening of core bioactive components, key targets, and relevant pathways to support future experimental validation and clinical research.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049422","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:42Z","timestamp":1782108042000},"page":"e49422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic insights into Tuoli Xiaozheng Formula for hepatocellular carcinoma: An integrated network pharmacology, molecular docking, and Mendelian randomization analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Jianhua","family":"Liang","sequence":"first","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, ShunDe Hospital of Guangzhou University of Chinese Medicine, Foshan, Guangdong Province, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Xu","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexian","family":"Shi","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Liao","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"He","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Xie","sequence":"additional","affiliation":[{"name":"Dongguan Hospital of Traditional Chinese Medicine, Dongguan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.3390\/jcm14176006","article-title":"Revealing new trends in the global burden of hepatocellular cancer related to hepatitis C virus by region, sociodemographic index, and sex.","volume":"14","author":"Sequeira","year":"2025","journal-title":"J Clin Med"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","article-title":"Goals and targets for personalized therapy for HCC.","volume":"13","author":"Couri","year":"2019","journal-title":"Hepatol Int"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamasurg.2022.5697","article-title":"Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma.","volume":"158","author":"Di Benedetto","year":"2023","journal-title":"JAMA Surg"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma.","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5582\/bst.2015.01019","article-title":"The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only the terminal stage of cancer.","volume":"9","author":"Qi","year":"2015","journal-title":"Biosci Trends"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/biom9080362","article-title":"The methodological trends of traditional herbal medicine employing network pharmacology.","volume":"9","author":"Lee","year":"2019","journal-title":"Biomolecules"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances.","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/biomedicines9111639","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma.","volume":"9","author":"Sun","year":"2021","journal-title":"Biomedicines"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/pharmaceutics15082130","article-title":"Targeting EGFR\/PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma.","volume":"15","author":"Bang","year":"2023","journal-title":"Pharmaceutics"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma.","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1002\/cam4.2388","article-title":"Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2\/STAT3 signaling pathway.","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/tox.23316","article-title":"Kaempferol inhibits the cell migration of human hepatocellular carcinoma cells by suppressing MMP-9 and Akt signaling.","volume":"36","author":"Ju","year":"2021","journal-title":"Environ Toxicol"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"155225","DOI":"10.1016\/j.phymed.2023.155225","article-title":"Stigmasterol: remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma.","volume":"129","author":"Huo","year":"2024","journal-title":"Phytomedicine"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13046-024-03208-3","article-title":"Correction: Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.","volume":"43","author":"Cai","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4149\/gpb_2019038","article-title":"Isorhamnetin induces ROS-dependent cycle arrest at G2\/M phase and apoptosis in human hepatocarcinoma Hep3B cells.","volume":"38","author":"Choi","year":"2019","journal-title":"Gen Physiol Biophys"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer.","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41420-020-0287-y","article-title":"The role of MDM2\u2013p53 axis dysfunction in the hepatocellular carcinoma transformation.","volume":"6","author":"Cao","year":"2020","journal-title":"Cell Death Discov"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/356215a0","article-title":"Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.","volume":"356","author":"Donehower","year":"1992","journal-title":"Nature"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/hep.510270411","article-title":"The mouse equivalent of the human p53Ser249 mutation p53Ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice.","volume":"27","author":"Ghebranious","year":"1998","journal-title":"Hepatology"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","article-title":"High metastatic potential in mice inheriting a targeted p53 missense mutation.","volume":"97","author":"Liu","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2020.04.003","article-title":"DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.","volume":"483","author":"Yao","year":"2020","journal-title":"Cancer Lett"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.2147\/IJN.S101285","article-title":"Upregulation of Akt\/NF-\u03baB-regulated inflammation and Akt\/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle.","volume":"11","author":"Tang","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.30697","article-title":"The mTORC2\u2013Akt1 cascade is crucial for c-Myc to promote hepatocarcinogenesis in mice and humans.","volume":"70","author":"Xu","year":"2019","journal-title":"Hepatology"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/13813455.2015.1048693","article-title":"Glucagon phosphorylates serine 552 of \u03b2-catenin leading to increased expression of cyclin D1 and c-Myc in the isolated rat liver.","volume":"121","author":"Chowdhury","year":"2015","journal-title":"Arch Physiol Biochem"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma.","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"R27-20261113","first-page":"6438","article-title":"Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.","volume":"7","author":"Zhen","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7150\/ijbs.7.536","article-title":"Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.","volume":"7","author":"Wang","year":"2011","journal-title":"Int J Biol Sci"},{"key":"R29-20261113","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/onc.2008.448","article-title":"The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-\u03b2 signaling.","volume":"28","author":"Lin","year":"2009","journal-title":"Oncogene"},{"key":"R30-20261113","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2007.04.017","article-title":"Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.","volume":"47","author":"Kusaba","year":"2007","journal-title":"J Hepatol"},{"key":"R31-20261113","doi-asserted-by":"crossref","first-page":"27429","DOI":"10.1074\/jbc.M110.142752","article-title":"Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.","volume":"285","author":"Liu","year":"2010","journal-title":"J Biol Chem"},{"key":"R32-20261113","doi-asserted-by":"crossref","first-page":"e13271","DOI":"10.1111\/sji.13271","article-title":"IL-6 upregulates the expression of IL-6R through the JAK2\/STAT3 signalling pathway to promote progression of hepatocellular carcinoma.","volume":"98","author":"Song","year":"2023","journal-title":"Scand J Immunol"},{"key":"R33-20261113","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.febslet.2013.11.033","article-title":"TNF-\u03b1 mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-\u03baB activation in liver cells.","volume":"588","author":"Kastl","year":"2014","journal-title":"FEBS Lett"},{"key":"R34-20261113","first-page":"565","article-title":"Hypoxia-inducible factor-1\u03b1 downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and enhances radiosensitivity in chemical hypoxic human hepatoma SMMC-7721 cells.","volume":"26","author":"Yang","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"R35-20261113","first-page":"573","article-title":"Role of hypoxia-inducible-1\u03b1 in hepatocellular carcinoma cells using a Tet-on inducible system to regulate its expression in vitro.","volume":"27","author":"Xu","year":"2012","journal-title":"Oncol Rep"},{"key":"R36-20261113","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2174\/0115680096262915231026050602","article-title":"Withaferin A inhibits liver cancer tumorigenesis by suppressing aerobic glycolysis through the p53\/IDH1\/HIF-1\u03b1 signaling axis.","volume":"24","author":"Zhou","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"R37-20261113","doi-asserted-by":"crossref","first-page":"e2411719","DOI":"10.1002\/advs.202411719","article-title":"Targeting FDFT1 reduces cholesterol and bile acid production and delays hepatocellular carcinoma progression through the HNF4A\/ALDOB\/AKT1 axis.","volume":"12","author":"Cai","year":"2025","journal-title":"Adv Sci"},{"key":"R38-20261113","doi-asserted-by":"crossref","first-page":"153575","DOI":"10.1016\/j.phymed.2021.153575","article-title":"Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT\/CyclinD1\/p21\/p27 pathway.","volume":"87","author":"Yang","year":"2021","journal-title":"Phytomedicine"},{"key":"R39-20261113","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12964-024-01573-2","article-title":"SUMOylation of annexin A6 retards cell migration and tumor growth by suppressing RHOU\/AKT1-involved EMT in hepatocellular carcinoma.","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"R40-20261113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3350\/cmh.2024.0934","article-title":"Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma.","volume":"31","author":"Zeng","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"R41-20261113","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3390\/ijms25042168","article-title":"All three AKT isoforms can upregulate oxygen metabolism and lactate production in human hepatocellular carcinoma cell lines.","volume":"25","author":"Tian","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R42-20261113","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization.","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"R43-20261113","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer.","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"R44-20261113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-1-4","article-title":"Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models.","volume":"1","author":"Schiaffino","year":"2011","journal-title":"Skelet Muscle"},{"key":"R45-20261113","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ccell.2016.02.008","article-title":"Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms.","volume":"29","author":"Wang","year":"2016","journal-title":"Cancer Cell"},{"key":"R46-20261113","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/2159-8290.CD-RW2016-056","article-title":"Hepatic deletion of AKT1 and AKT2 induces hepatocellular carcinoma.","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"R47-20261113","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s13046-024-03207-4","article-title":"AKT kinases as therapeutic targets.","volume":"43","author":"Hassan","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"R48-20261113","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.21037\/tcr.2016.08.22","article-title":"Akt1\/Akt2 inhibition and development of hepatocellular carcinoma.","volume":"5","author":"Critelli","year":"2016","journal-title":"Transl Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:48Z","timestamp":1794585648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":48,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049422","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}